269 related articles for article (PubMed ID: 28882621)
1. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade.
Grabmeier-Pfistershammer K; Stecher C; Zettl M; Rosskopf S; Rieger A; Zlabinger GJ; Steinberger P
Clin Immunol; 2017 Oct; 183():167-173. PubMed ID: 28882621
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
3. Combination Immune Checkpoint Blockade to Reverse HIV Latency.
Van der Sluis RM; Kumar NA; Pascoe RD; Zerbato JM; Evans VA; Dantanarayana AI; Anderson JL; Sékaly RP; Fromentin R; Chomont N; Cameron PU; Lewin SR
J Immunol; 2020 Mar; 204(5):1242-1254. PubMed ID: 31988180
[TBL] [Abstract][Full Text] [Related]
4. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
[TBL] [Abstract][Full Text] [Related]
7. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
[TBL] [Abstract][Full Text] [Related]
8. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
9. Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.
Chiu CY; Chang JJ; Dantanarayana AI; Solomon A; Evans VA; Pascoe R; Gubser C; Trautman L; Fromentin R; Chomont N; McMahon JH; Cameron PU; Rasmussen TA; Lewin SR
J Immunol; 2022 Jan; 208(1):54-62. PubMed ID: 34853078
[TBL] [Abstract][Full Text] [Related]
10. PD-1 has a unique capacity to inhibit allergen-specific human CD4
Rosskopf S; Jahn-Schmid B; Schmetterer KG; Zlabinger GJ; Steinberger P
Sci Rep; 2018 Sep; 8(1):13543. PubMed ID: 30201974
[TBL] [Abstract][Full Text] [Related]
11. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
12. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.
Vali B; Jones RB; Sakhdari A; Sheth PM; Clayton K; Yue FY; Gyenes G; Wong D; Klein MB; Saeed S; Benko E; Kovacs C; Kaul R; Ostrowski MA
Eur J Immunol; 2010 Sep; 40(9):2493-505. PubMed ID: 20623550
[TBL] [Abstract][Full Text] [Related]
13. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS; Rothe M; Schnorfeil FM; Deiser K; Krupka C; Augsberger C; Schlüter M; Neitz J; Subklewe M
Front Immunol; 2018; 9():385. PubMed ID: 29535740
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.
Seung E; Dudek TE; Allen TM; Freeman GJ; Luster AD; Tager AM
PLoS One; 2013; 8(10):e77780. PubMed ID: 24204962
[TBL] [Abstract][Full Text] [Related]
15. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.
Hoffmann M; Pantazis N; Martin GE; Hickling S; Hurst J; Meyerowitz J; Willberg CB; Robinson N; Brown H; Fisher M; Kinloch S; Babiker A; Weber J; Nwokolo N; Fox J; Fidler S; Phillips R; Frater J;
PLoS Pathog; 2016 Jul; 12(7):e1005661. PubMed ID: 27415828
[TBL] [Abstract][Full Text] [Related]
16. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
[TBL] [Abstract][Full Text] [Related]
18. T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation.
Bouvy AP; Klepper M; Kho MM; Ijzermans JN; Betjes MG; Weimar W; Baan CC
Transplantation; 2015 Sep; 99(9):1995-2003. PubMed ID: 25769075
[TBL] [Abstract][Full Text] [Related]
19. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
20. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
